{"id":511253,"date":"2021-07-09T00:51:48","date_gmt":"2021-07-09T04:51:48","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/cti-biopharma-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-8\/"},"modified":"2021-07-09T00:51:48","modified_gmt":"2021-07-09T04:51:48","slug":"cti-biopharma-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-8","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cti-biopharma-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-8\/","title":{"rendered":"CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n SEATTLE<\/span>, July 8, 2021<\/span> \/PRNewswire\/ — CTI BioPharma Corp. (NASDAQ: CTIC) today announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted an equity award to a new employee as an equity inducement award outside of the Company’s Amended and Restated 2017 Equity Incentive Plan (but under the terms of the Amended and Restated 2017 Equity Incentive Plan) and material to the employee’s acceptance of employment with the company. The equity award was approved on July 8, 2021<\/span>, in accordance with Nasdaq Listing Rule 5635(c)(4). <\/p>\n

The employee received options to purchase 12,000 shares of CTI BioPharma common stock. The options will be issued upon the employee’s grant date (the “Grant Date”), and all stock options included within the equity inducement award will have an exercise price equal to the closing price of CTI BioPharma common stock on the Grant Date. One-fourth of the options will vest on each anniversary of the employee’s Grant Date, subject to the employee’s continued employment with CTI BioPharma on such vesting dates. The options have a ten-year term.<\/p>\n

\n About CTI BioPharma Corp.
<\/b>We are a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. We concentrate our efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, we are focused on evaluating pacritinib, our sole product candidate currently in active late-stage development, for the treatment of adult patients with myelofibrosis. In addition, we have recently started developing pacritinib for use in hospitalized patients with severe COVID-19, in response to the COVID-19 pandemic. We are headquartered in Seattle, Washington<\/span>.<\/p>\n

\n CTI BioPharma Investor\u00a0Contacts:
<\/b>
\n Maeve Conneighton<\/span>\/Maghan\u00a0Meyers
+212-600-1902
cti@argotpartners.com<\/a>\u00a0<\/p>\n

\n

\n
\n \"CTI
\n <\/a>\n <\/p>\n<\/p><\/div>\n

\u00a0<\/p>\n

<\/div>\n

\n \"Cision\" View original content to download multimedia:https:\/\/www.prnewswire.com\/news-releases\/cti-biopharma-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-301328506.html<\/a><\/p>\n

SOURCE CTI BioPharma Corp.<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire SEATTLE, July 8, 2021 \/PRNewswire\/ — CTI BioPharma Corp. (NASDAQ: CTIC) today announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted an equity award to a new employee as an equity inducement award outside of the Company’s Amended and Restated 2017 Equity Incentive Plan (but under the terms of the Amended and Restated 2017 Equity Incentive Plan) and material to the employee’s acceptance of employment with the company. The equity award was approved on July 8, 2021, in accordance with Nasdaq Listing Rule 5635(c)(4). The employee received options to purchase 12,000 shares of CTI BioPharma common stock. The options will be issued upon the employee’s grant date (the “Grant Date”), and all … <\/p>\n

Continue reading “CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-511253","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nCTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cti-biopharma-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-8\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire SEATTLE, July 8, 2021 \/PRNewswire\/ — CTI BioPharma Corp. (NASDAQ: CTIC) today announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted an equity award to a new employee as an equity inducement award outside of the Company’s Amended and Restated 2017 Equity Incentive Plan (but under the terms of the Amended and Restated 2017 Equity Incentive Plan) and material to the employee’s acceptance of employment with the company. The equity award was approved on July 8, 2021, in accordance with Nasdaq Listing Rule 5635(c)(4). The employee received options to purchase 12,000 shares of CTI BioPharma common stock. The options will be issued upon the employee’s grant date (the “Grant Date”), and all … Continue reading "CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cti-biopharma-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-8\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-09T04:51:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/92552\/cell_therapeutics_inc_cti_biopharma_corp_logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cti-biopharma-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-8\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cti-biopharma-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-8\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)\",\"datePublished\":\"2021-07-09T04:51:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cti-biopharma-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-8\\\/\"},\"wordCount\":324,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cti-biopharma-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-8\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/92552\\\/cell_therapeutics_inc_cti_biopharma_corp_logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cti-biopharma-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-8\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cti-biopharma-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-8\\\/\",\"name\":\"CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cti-biopharma-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-8\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cti-biopharma-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-8\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/92552\\\/cell_therapeutics_inc_cti_biopharma_corp_logo.jpg\",\"datePublished\":\"2021-07-09T04:51:48+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cti-biopharma-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-8\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cti-biopharma-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-8\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cti-biopharma-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-8\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/92552\\\/cell_therapeutics_inc_cti_biopharma_corp_logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/92552\\\/cell_therapeutics_inc_cti_biopharma_corp_logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cti-biopharma-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-8\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cti-biopharma-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-8\/","og_locale":"en_US","og_type":"article","og_title":"CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","og_description":"PR Newswire SEATTLE, July 8, 2021 \/PRNewswire\/ — CTI BioPharma Corp. (NASDAQ: CTIC) today announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted an equity award to a new employee as an equity inducement award outside of the Company’s Amended and Restated 2017 Equity Incentive Plan (but under the terms of the Amended and Restated 2017 Equity Incentive Plan) and material to the employee’s acceptance of employment with the company. The equity award was approved on July 8, 2021, in accordance with Nasdaq Listing Rule 5635(c)(4). The employee received options to purchase 12,000 shares of CTI BioPharma common stock. The options will be issued upon the employee’s grant date (the “Grant Date”), and all … Continue reading \"CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cti-biopharma-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-8\/","og_site_name":"Market Newsdesk","article_published_time":"2021-07-09T04:51:48+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/92552\/cell_therapeutics_inc_cti_biopharma_corp_logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cti-biopharma-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-8\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cti-biopharma-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-8\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","datePublished":"2021-07-09T04:51:48+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cti-biopharma-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-8\/"},"wordCount":324,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cti-biopharma-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-8\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/92552\/cell_therapeutics_inc_cti_biopharma_corp_logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cti-biopharma-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-8\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cti-biopharma-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-8\/","name":"CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cti-biopharma-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-8\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cti-biopharma-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-8\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/92552\/cell_therapeutics_inc_cti_biopharma_corp_logo.jpg","datePublished":"2021-07-09T04:51:48+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cti-biopharma-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-8\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cti-biopharma-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-8\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cti-biopharma-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-8\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/92552\/cell_therapeutics_inc_cti_biopharma_corp_logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/92552\/cell_therapeutics_inc_cti_biopharma_corp_logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cti-biopharma-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-8\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/511253","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=511253"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/511253\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=511253"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=511253"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=511253"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}